Bjørn Tore Gjertsen • 1966 • Morvik • 7 roles • 8 shareholdings

This website uses cookies to enhance the user experience.

||

Roles

Management

Name	Role	Total operating income	Total equity	Shares
T TRES BIOTECHNOLOGY AS	Managing Director/CEO	-	147,767	50 % directly

Boards

Name	Role	Total operating income	Total equity	Shares
K KINN THERAPEUTICS AS	Board Member	3,040,284	2,636,391	50 % directly
T TRES BIOTECHNOLOGY AS	Chairman	-	147,767	50 % directly
Y YZ HOLDING AS	Board Member	-	452,884	40 % directly
H HÁ BIOTECH AS	Board Member	-	-	40 % directly
A ALDEN CANCER THERAPY AS	Board Member	-	1,432,006	23.57 % indirectly
B BJØRGVIN THERAPEUTICS GROUP AS	Board Member	-	-46,641	7.25 % indirectly

Last update: Feb 14, 2026

Related industries1

Industry and manufacturing
/ Process industry

Direct relationships5

KH
Karl Henning Kalland1955
ALDEN CANCER THERAPY AS, YZ HOLDING AS
AM
Anne Margrete Øyan1949
ALDEN CANCER THERAPY AS, YZ HOLDING AS
ØE
Øivind Enger1956
HÁ BIOTECH AS
MS
Marcel Sandberg1969
BJØRGVIN THERAPEUTICS GROUP AS
SK
Stener Kvinnsland1948
ALDEN CANCER THERAPY AS

Shares owned by Bjørn Tore Gjertsen

Name	Share class	Total operating income	Total equity	Share
T TRES BIOTECHNOLOGY AS	Ordinære aksjer	0	147,767	50 % directly
K KINN THERAPEUTICS AS	Ordinære aksjer	3,040,284	2,636,391	50 % directly
Y YZ HOLDING AS	Ordinære aksjer	0	452,884	40 % directly
H HÁ BIOTECH AS	Ordinære aksjer	0	0	40 % directly
A ALDEN CANCER THERAPY AS		0	1,432,006	23.57 % indirectly
B BJØRGVIN THERAPEUTICS GROUP AS		0	-46,641	7.25 % indirectly
L LEDIDI AS	Ordinære aksjer	24,489,960	13,057,051	< 0.01 % directly
O ONCOINVENT ASA	NO0013251173	1,909,000	122,658,000	< 0.01 % directly

Limited to direct ownership positions of 0.5% or more.

Last update: Jun 2, 2025